Society of surgical oncology presidential address: The war on cancer-shifting from disappointment to new hope

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 1971-1978

  Cance, William G ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; IMATINIB; TAMOXIFEN; TRASTUZUMAB;

CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAREER; CONFERENCE PAPER; HUMAN; LEADERSHIP; MEDICAL SOCIETY; PANCREAS CANCER; PANCREATICODUODENECTOMY; SURGEON; SURGICAL TRAINING; SURVIVAL RATE; SURVIVAL TIME; TEACHER; FEMALE; MALE; MORTALITY; NEOPLASMS; ORGANIZATION AND MANAGEMENT; TRENDS; UNITED STATES;

FEMALE; HUMANS; MALE; NEOPLASMS; NEW YORK; SOCIETIES, MEDICAL; SURVIVAL RATE;

EID: 77954956102     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-0987-2     Document Type: Conference Paper

References (7)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-13.
2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-6.
3. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009;27(3):328-33.
4. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619-26.
5. Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer. Histol Histopathol. 2009;24(4):503-10.
6. Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal. 2008;1(20):pe22.
7. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320(5873):226-30.